查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1671137

骨髓惡性腫瘤治療藥的全球市場:市場規模·佔有率·趨勢，產業分析 (各疾病·各治療法·各最終用途·各地區)，未來預測 (2025年～2034年)

Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，血液系統惡性腫瘤藥物市場預計到 2034 年將達到 1,481.5 億美元。該報告提供了有關當前市場動態的詳細見解，並對未來市場的成長進行了分析。

血液系統惡性腫瘤藥物是指用於治療血癌的療法，包括白血病、淋巴瘤和骨髓瘤。這些癌症會影響血液、骨髓、淋巴系統和脾臟，需要專門的治療方法。受白血病、淋巴瘤、骨髓瘤等血癌發病率不斷上升以及治療方案不斷改進的推動，血液系統惡性腫瘤藥物的市場佔有率正在顯著增長。主要推動因素包括CAR-T細胞療法和單株抗體等免疫療法的興起，以及提供更精準治療且副作用更少的標靶療法的日益普及。聯合療法、個人化醫療和生物相似藥的推廣也帶來了機遇，這些療法為傳統治療提供了具有成本效益的替代方案。此外，正在進行的研究、臨床試驗和新療法的監管批准繼續推動市場創新。透過轉向門診治療來改善患者就醫機會以及注重減少治療抵抗等趨勢正在促進市場的整體擴張，預計未來幾年市場將繼續增長。

血液系統惡性腫瘤藥物市場：分析概述

由於慢性淋巴細胞白血病 (CLL) 和急性髓細胞白血病 (AML) 等疾病的發生率很高，白血病在市場佔有率方面佔據主導地位。標靶治療的重大進展正在推動成長。然而，由於 CAR-T 細胞療法等免疫療法的採用日益廣泛，淋巴瘤成為成長最快的領域。

免疫療法佔據血液系統惡性腫瘤治療市場的最大佔有率，其中CAR-T細胞療法和單株抗體在改變血液系統惡性腫瘤治療方面發揮關鍵作用。隨著精準醫療不斷改善血癌患者的治療效果並減少副作用，標靶治療正在實現最快的成長。

醫院藥房佔據了最大的市場佔有率，因為它們在提供 CAR-T 細胞療法和化療等複雜治療方面發揮著核心作用。零售藥局是成長最快的領域，這得益於對口服溶瘤藥物和家庭治療方案的需求不斷增長。

北美因其較高的治療可及性、先進的醫療基礎設施以及對新療法的監管支持而佔據市場主導地位。由於癌症發生率的增加、醫療保健機會的改善以及對治療創新的投資，亞太地區是成長最快的地區。

目錄

第1章 簡介

第2章 摘要整理

第3章 分析方法

第4章 骨髓惡性腫瘤治療藥市場洞察

  • 市場概述
  • 骨髓惡性腫瘤治療藥的市場動態
    • 促進因素和機會
      • 整合人工智慧與機器學習
      • 過渡到高通量實驗
    • 阻礙因素與課題
      • 資料數量的不足
  • 大環境分析
  • 骨髓惡性腫瘤治療藥市場趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球骨髓惡性腫瘤治療藥市場:各疾病

  • 主要的分析結果
  • 簡介
  • 白血病
  • 淋巴瘤
  • 骨髓瘤

第6章 全球骨髓惡性腫瘤治療藥市場:各治療法

  • 主要的分析結果
  • 簡介
  • 化療
  • 免疫療法
  • 標靶治療
  • 其他

第7章 全球骨髓惡性腫瘤治療藥市場:各最終用途

  • 主要的分析結果
  • 簡介
  • 醫院藥局
  • 其他

第8章 全球骨髓惡性腫瘤治療藥市場:各地區

  • 主要的分析結果
  • 簡介
    • 骨髓惡性腫瘤治療藥市場評估:各地區 (2020～2034年)
  • 北美
    • 北美:疾病 (2020～2034年)
    • 北美:各治療法 (2020～2034年)
    • 北美:各最終用途 (2020～2034年)
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:疾病 (2020～2034年)
    • 歐洲:各治療法 (2020～2034年)
    • 歐洲:各最終用途 (2020～2034年)
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 亞太地區:疾病 (2020～2034年)
    • 亞太地區:各治療法 (2020～2034年)
    • 亞太地區:各最終用途 (2020～2034年)
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東·非洲:疾病 (2020～2034年)
    • 中東·非洲:各治療法 (2020～2034年)
    • 中東·非洲:各最終用途 (2020～2034年)
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東·非洲
  • 南美
    • 南美:疾病 (2020～2034年)
    • 南美:各治療法 (2020～2034年)
    • 南美:各最終用途 (2020～2034年)
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美國家

第9章 競爭情形

  • 事業擴大·企業收購的分析
    • 事業擴大
    • 企業收購
  • 聯盟/合作/協定/公開

第10章 企業簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • BeiGene
  • Kite Pharma(a subsidiary of Gilead Sciences)
  • Celgene Corporation(acquired by Bristol-Myers Squibb)
  • Regeneron Pharmaceuticals, Inc.
Product Code: PM1347

The hematologic malignancies therapeutics market size is expected to reach USD 148.15 billion by 2034, according to a new study by Polaris Market Research. The report "Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Leukemia, Lymphoma, and Myeloma), Therapy, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hematologic malignancies therapeutics refer to the medical treatments used to manage blood cancers, which include leukemia, lymphoma, and myeloma. These cancers affect the blood, bone marrow, lymphatic system, or spleen and require specialized therapeutic approaches. The hematologic malignancies therapeutics market share is experiencing significant growth, driven by increasing incidence rates of blood cancers such as leukemia, lymphoma, and myeloma, alongside advancements in treatment options. Key drivers include the rise of immunotherapies, such as CAR-T cell therapies and monoclonal antibodies, as well as the growing adoption of targeted therapies that offer more precise treatment with fewer side effects. Opportunities are emerging in the development of combination therapies, personalized medicine, and the expansion of biosimilars, providing cost-effective alternatives to traditional treatments. Additionally, ongoing research, clinical trials, and regulatory approvals for new therapies continue to drive innovation in the market. Trends such as a shift toward outpatient care increased patient access, and a focus on reducing treatment resistance contribute to the market's overall expansion, positioning it for continued growth in the coming years.

Hematologic Malignancies Therapeutics Market Report Highlights

Leukemia dominates the market in terms of market share due to the high prevalence of conditions such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Significant advancements in targeted therapies are driving its growth. However, lymphoma is the fastest growing segment, driven by the increasing adoption of immunotherapies such as CAR-T cell therapies.

Immunotherapy holds the largest hematologic malignancies therapeutics market share, with CAR-T cell therapies and monoclonal antibodies playing a crucial role in transforming the treatment of hematologic malignancies. Targeted therapies are registering the fastest growth as precision treatments continue to improve outcomes and reduce side effects in blood cancer patients.

Hospital pharmacies hold the largest market share due to their central role in administering complex treatments such as CAR-T cell therapies and chemotherapy. Retail pharmacies are the fastest growing segment, supported by the rising demand for oral oncolytics and at-home treatment options.

North America dominates the market due to high treatment accessibility, advanced healthcare infrastructure, and regulatory support for new therapies. Asia Pacific is the fastest growing region, fueled by increasing cancer incidence, improving healthcare access, and investment in treatment innovations.

Polaris Market Research has segmented the hematologic malignancies therapeutics market report based on disease, therapy, end use, and region:

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

  • Leukemia
  • Lymphoma
  • Myeloma

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Others

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Hematologic Malignancies Therapeutics Market Insights

  • 4.1. Hematologic Malignancies Therapeutics Market - Market Snapshot
  • 4.2. Hematologic Malignancies Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Integration of AI and Machine Learning
      • 4.2.1.2. Shift Toward High-Throughput Experimentation
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Insufficient data volume
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Hematologic Malignancies Therapeutics Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Hematologic Malignancies Therapeutics Market, by Disease

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • 5.3. Leukemia
    • 5.3.1. Global Hematologic Malignancies Therapeutics Market, by Leukemia, by Region, 2020-2034 (USD Billion)
  • 5.4. Lymphoma
    • 5.4.1. Global Hematologic Malignancies Therapeutics Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
  • 5.5. Myeloma
    • 5.5.1. Global Hematologic Malignancies Therapeutics Market, by Myeloma, by Region, 2020-2034 (USD Billion)

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Hematologic Malignancies Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Hematologic Malignancies Therapeutics Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 6.5. Targeted Therapy
    • 6.5.1. Global Hematologic Malignancies Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Hematologic Malignancies Therapeutics Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Hematologic Malignancies Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Others
    • 7.4.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Hematologic Malignancies Therapeutics Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Hematologic Malignancies Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Hematologic Malignancies Therapeutics Market - North America
    • 8.3.1. North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.3.2. North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.3.3. North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.4. Hematologic Malignancies Therapeutics Market - U.S.
      • 8.3.4.1. U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.5. Hematologic Malignancies Therapeutics Market - Canada
      • 8.3.5.1. Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.4. Hematologic Malignancies Therapeutics Market - Europe
    • 8.4.1. Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.4. Hematologic Malignancies Therapeutics Market - UK
      • 8.4.4.1. UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.5. Hematologic Malignancies Therapeutics Market - France
      • 8.4.5.1. France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.6. Hematologic Malignancies Therapeutics Market - Germany
      • 8.4.6.1. Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.7. Hematologic Malignancies Therapeutics Market - Italy
      • 8.4.7.1. Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.8. Hematologic Malignancies Therapeutics Market - Spain
      • 8.4.8.1. Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.9. Hematologic Malignancies Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.10. Hematologic Malignancies Therapeutics Market - Russia
      • 8.4.10.1. Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.11. Hematologic Malignancies Therapeutics Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.5. Hematologic Malignancies Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.4. Hematologic Malignancies Therapeutics Market - China
      • 8.5.4.1. China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.5. Hematologic Malignancies Therapeutics Market - India
      • 8.5.5.1. India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.6. Hematologic Malignancies Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.7. Hematologic Malignancies Therapeutics Market - Japan
      • 8.5.7.1. Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.8. Hematologic Malignancies Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.9. Hematologic Malignancies Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.10. Hematologic Malignancies Therapeutics Market - Australia
      • 8.5.10.1. Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.11. Hematologic Malignancies Therapeutics Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.6. Hematologic Malignancies Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.4. Hematologic Malignancies Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.5. Hematologic Malignancies Therapeutics Market - UAE
      • 8.6.5.1. UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.6. Hematologic Malignancies Therapeutics Market - Israel
      • 8.6.6.1. Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.7. Hematologic Malignancies Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.8. Hematologic Malignancies Therapeutics Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.7. Hematologic Malignancies Therapeutics Market - Latin America
    • 8.7.1. Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.4. Hematologic Malignancies Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.5. Hematologic Malignancies Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.6. Hematologic Malignancies Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.7. Hematologic Malignancies Therapeutics Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Amgen Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bristol-Myers Squibb Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. F. Hoffmann-La Roche Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Gilead Sciences Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson & Johnson
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck & Co., Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Takeda Pharmaceutical Company Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. AstraZeneca
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. BeiGene
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Kite Pharma (a subsidiary of Gilead Sciences)
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Celgene Corporation (acquired by Bristol-Myers Squibb)
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Regeneron Pharmaceuticals, Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables:

  • Table 1 Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 2 Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 3 Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 4 North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 5 North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 6 North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 8 U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 9 U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 10 Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 11 Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 12 Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 14 Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 15 Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 16 UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 17 UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 18 UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 20 France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 21 France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 22 Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 23 Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 24 Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 26 Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 27 Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 28 Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 29 Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 30 Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 34 Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 35 Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 36 Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 44 China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 45 China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 46 India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 47 India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 48 India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 52 Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 53 Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 54 Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 58 South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 59 South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 60 South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 62 Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 63 Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 73 UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 74 UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 75 UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 76 Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 77 Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 78 Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 79 South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 80 South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 81 South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 85 Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 86 Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 87 Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 88 Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 89 Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 90 Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 91 Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 92 Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 93 Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 94 Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 95 Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 96 Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Hematologic Malignancies Therapeutics Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Disease
  • Figure 7. Global Hematologic Malignancies Therapeutics Market, by Disease, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy
  • Figure 9. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2024 & 2034 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Hematologic Malignancies Therapeutics Market, by End Use, 2024 & 2034 (USD Billion)